Tryin
Trying on the underlying holdings of the ETFs in our protection universe at ETF Channel, we have now in contrast the buying and selling worth of every holding towards the typical analyst 12-month ahead goal worth, and computed the weighted common implied analyst goal worth for the ETF itself. For the Invesco Dynamic Biotechnology & Genome ETF (Image: PBE), we discovered that the implied analyst goal worth for the ETF based mostly upon its underlying holdings is $61.97 per unit.
With PBE buying and selling at a latest worth close to $56.55 per unit, that signifies that analysts see 9.58% upside for this ETF trying by means of to the typical analyst targets of the underlying holdings. Three of PBE’s underlying holdings with notable upside to their analyst goal costs are Enanta Prescription drugs Inc (Image: ENTA), Corcept Therapeutics Inc (Image: CORT), and Bausch Well being Firms Inc (Image: BHC). Though ENTA has traded at a latest worth of $64.55/share, the typical analyst goal is 48.72% larger at $96.00/share. Equally, CORT has 21.16% upside from the latest share worth of $12.65 if the typical analyst goal worth of $15.33/share is reached, and analysts on common are…